MAXAIR
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAIR is a metered-dose aerosol inhaler approved in 1986 for inhalation delivery. The specific indication and mechanism of action are not documented in available data. This is a legacy small-molecule product with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team priorities likely shifting toward lifecycle management and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXAIR represents a mature product approaching loss of exclusivity, offering limited growth opportunities but important experience in brand defense and generic transition strategy. Career progression on this product emphasizes cost management, payer negotiations, and competitive positioning rather than new market development.
Brand ManagerMarket Access Manager
Worked on MAXAIR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.